Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - The core focus of institutional research this week (February 9 to February 13) was on 71 listed companies, with Tianshun Wind Power receiving the most attention from 237 participating institutions [1] - Other companies that attracted significant institutional interest include Nanmin Group, Guoneng Rixin, and Doli Technology, with 51, 39, and 35 institutions respectively conducting research on them [1] - In terms of industry focus, institutions are continuing to concentrate on sectors such as industrial machinery, automotive parts and equipment, and non-metallic metals [1]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Hunan Fangsheng Pharmaceutical Co., Ltd., Zhang Qinghua, indicating a controlled risk level associated with the pledged shares [2][3]. Group 1: Share Pledge Details - Zhang Qinghua has completed the pledge of 8.75 million shares, representing 1.99% of the company's total share capital [2]. - As of the announcement date, Zhang Qinghua directly holds 156,019,500 shares, which is 35.53% of the total shares (439,081,360 shares) [2]. - The total number of pledged shares by Zhang Qinghua is 64,075,200, accounting for 41.07% of his directly held shares and 14.59% of the company's total shares [2]. Group 2: Pledge Risk Assessment - The total pledged shares by Zhang Qinghua and his concerted parties amount to 64,075,200, which is 38.70% of their total holdings, and the pledge ratio does not exceed 80%, indicating manageable risk [2][6]. - Zhang Qinghua's personal credit status is good, and he is planning for the upcoming maturity of pledged shares, with no substantial default risk anticipated [6]. Group 3: Impact on Company Operations - The pledged shares are primarily for replacing other maturing financing, and this action will not significantly impact the company's main business, financing costs, or operational sustainability [6]. - The pledge will not adversely affect the company's governance or daily management, nor will it lead to a change in actual control of the company [6].

Group 1 - Company Fangsheng Pharmaceutical announced on February 11, 2026, that its controlling shareholder and actual controller, Mr. Zhang Qinghua, has completed the procedures for pledging part of his shares, with a total of 8.75 million shares pledged [1] - The announcement indicates a significant movement in the company's shareholding structure, which may impact investor sentiment and stock performance [1] Group 2 - The industry is witnessing a surge in stock prices related to film and video production, driven by advancements in AI technology, particularly a new Chinese video model capable of generating 15-second videos from a few prompts [1] - This technological innovation is being referred to as the "strongest on the planet," suggesting a competitive edge for companies involved in the film and entertainment sector [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-010 湖南方盛制药股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华 先生办理完成了875万股（占公司总股本的1.99%）股份质押手续； ●截至本公告披露日，张庆华先生直接持有公司的股份总数为156,019,500股，占公 司股份总数（439,081,360股）的35.53%；张庆华先生质押的公司股份总数为64,075,200 股（含本次增加质押的股份），占其直接持有公司股份总数的41.07%，占公司股份总数 的14.59%；张庆华先生控股的湖南开舜投资咨询有限公司之控股子公司长沙共盛产投咨 询有限公司（原"泰州共生创业投资管理有限公司""泰州共生咨询有限公司"，以下 简称"共盛产投"）持有公司股份数为9,131,807股，共盛 ...

Group 1 - The controlling shareholder and actual controller Zhang Qinghua completed the pledge of 8.75 million shares, accounting for 1.99% of the total share capital, to replace maturing financing on February 11 [1] - As of the announcement date, Zhang Qinghua directly holds 156 million shares, representing 35.53% of the total share capital, with a cumulative pledge of 64.0752 million shares, which is 41.07% of his direct holdings and 14.59% of the total share capital [1] - Zhang Qinghua and his concerted parties collectively hold 166 million shares, with a cumulative pledge of 64.0752 million shares, accounting for 38.70% of the total holdings, indicating that the overall pledge risk is controllable and there is no risk of forced liquidation [1]

Core Viewpoint - Fangsheng Pharmaceutical emphasizes the importance of market value maintenance and has integrated it into the performance evaluation metrics of senior management [2] Group 1: Company Actions - The company is committed to improving its information disclosure mechanisms and enhancing communication with investors to foster a better understanding of its value [2] - Fangsheng Pharmaceutical adheres to a proactive and stable cash dividend policy to reward all shareholders [2] - The company focuses on the long-term sustainable development of its core business and aims to continuously strengthen operational management to drive stable growth and value creation [2]

数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：株冶集团（600961），新威凌（871634），岳阳兴长（000819），克明食品（002661），盐 津铺子（002847），劲仔食品（003000），绝味食品（603517），华升股份（600156），千金药业 （600479），方盛制药（603998），泰嘉股份（002843），宇环数控（002903），宇晶股份 （002943），三德科技（300515），岱勒新材（300700），华锐精密（688059） 2025年1-12月，湖南省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为21459 个，和上年同期相比，减少了302个，同比下降1.39%，占全国的比重为4.08%。 2016- ...

Investment Rating - The report upgrades the investment rating for the pharmaceutical and biotechnology industry to "Recommended" [1][42]. Core Insights - The pharmaceutical sector has shown resilience, with a year-to-date return of 3.28%, outperforming the Shanghai Composite Index by 2.99 percentage points [9][23]. - The report highlights the continuous support from policies, particularly for the traditional Chinese medicine (TCM) sector, which is expected to see significant growth due to government initiatives aimed at enhancing the industry [15][17]. - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that domestic companies are gradually improving their innovation capabilities [42]. Summary by Sections Recent Performance - The Shanghai Composite Index fell by 1.33% while the pharmaceutical sector rose by 0.14%, ranking 15th among 31 primary sub-industries [14][23]. - Within the pharmaceutical sub-sectors, traditional Chinese medicine, medical services, and other segments showed varying performance, with traditional Chinese medicine increasing by 2.56% [14][23]. Policy Developments - On February 5, 2026, the Ministry of Industry and Information Technology and other departments released the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," focusing on enhancing the resilience and stability of the TCM supply chain [15][17]. - The plan aims to improve the quality and stable supply of TCM materials and products, which is crucial for the long-term development of the industry [15][17]. Market Dynamics - The report notes that the TCM sector is expected to experience a recovery in performance starting from mid-2025, with improved financial results anticipated in 2026 [9][17]. - The comprehensive index for TCM materials has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies in 2026 [9][17]. Valuation Metrics - As of February 6, 2026, the pharmaceutical sector's valuation stands at 33.3 times PE, with a premium of 32% compared to the overall A-share market (excluding financials) [24]. - The TTM valuation is at 29.4 times PE, below the historical average of 34.9 times PE, indicating potential for growth [24]. Key Companies to Watch - The report suggests focusing on companies such as Aidi Pharmaceutical, Huadong Medicine, Kangnuo Pharmaceutical-B, and others, which are positioned well within the TCM sector and are expected to benefit from policy support and market dynamics [35][43].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].